Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10909532 | Leukemia Research | 2005 | 7 Pages |
Abstract
Lovastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase (HMGR), is used therapeutically to lower plasma cholesterol levels and has garnered attention for its cytotoxic effects in leukemia cells. In this study, escalating doses of lovastatin were administered to nine patients with acute myelogenous leukemia. Peripheral blood leukemia cells were drawn pre- and post-lovastatin dosing. Plasma lovastatin bioactivity ranged up to 234Â nM lovastatin equivalents. Our results show that in vivo lovastatin, at up to 200Â mg/dose, induces an increased activity of leukemia cell HMGR and alters leukemia cell proliferation without discernibly altering Ras processing.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Kriste A. Lewis, Sarah A. Holstein, Raymond J. Hohl,